MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Coherus BioSciences, Inc. (NASDAQ: CHRS)
Organization & Developments: Coherus
Parents
Coherus BioSciences, Inc. (NASDAQ: CHRS)
Children
*A Biosimilar Therapeutics Developer
*Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide.
*DEVELOPS PROTEIN-BASED THERAPEUTICS FOR THE TREATMENT OF VARIOUS INFLAMMATORY AND CHRONIC CONDITIONS.
2018: Coherus_This Small Biotech Could Chip Away At Sales Of Key Amgen Drug_www.investors.com
2019: How This IBD Stock Of The Day Is Rattling Medical Giants Amgen, Mylan_www.investors.com
2019: VA_65--Coherus BioScience, Inc. Contract Award Effective 8/15/2019 65IB, 36F79719D0216 Effective 8-15-2019
2021: Coherus BioSciences: Dependable Stock With A Possibility Of Appreciation
2021: Coherus: Transitioning To Its Next Avatar As An R&D Company
2023: Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade)_ seekingalpha.com
2023: Coherus: Launch Of Humira Biosimilar May Boost Stock_seekingalpha.com
2023: Coherus: The Surface Acquisition Is A Distraction
2023: Why I Am Exiting, But Also Why You May Want To Hold On (NASDAQ:CHRS)
2024: Coherus Biosciences: Dumping One Drug But Showing Promise With Another
2024: Coherus BioSciences: FDA Approvals Spice Up The Pipeline_ seekingalpha.com
2024: Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development_seekingalpha.com
2024: Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
2024:Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition Investing.com
Jumps
*Key People: Coherus
Finance & Acquisitions: Coherus